Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020655 | 0.83 | MAPT (0.52) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL10881094 | 0.83 | MAPT (0.52) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL11070858 | 0.81 | TDP1 (0.61) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL305090 | 0.79 | MAPK1 (0.58) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL10507643 | 0.78 | MAPT (0.52) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL28180778 | 0.78 | L3MBTL1 (0.57) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL7653421 | 0.78 | NPC1 (0.55) | MAPTKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL6975977 | 0.78 | GSK3B (0.57) | MAPTKMT2AMEN1CYP3A4HPGD | |
| SCHEMBL8612273 | 0.77 | TDP1 (0.56) | MAPTKMT2AMAPK1MEN1TDP1 | |
| SCHEMBL11196572 | 0.77 | GSK3B (0.58) | MAPTKMT2AMAPK1MEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102482399-A | Catalysis of epoxy resin formulations containing poorly soluble catalysts | EVONIK DEGUSSA GMBH | 2012-05-30 | — | — | CN | disclosed |
| CN-102414243-A | Catalysis of epoxy resin formulations | EVONIK DEGUSSA GMBH | 2012-04-11 | — | — | CN | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-1898244-B | Triazole derivatives as vasopressin antagonists | PFIZER | 2011-06-22 | — | — | CN | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| WO-2009106565-A1 | AGONISTS OF GPR119 | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106561-A1 | PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-5691341-A | ANTILEUKEMIA AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| CN-1156455-A | Nonel naphthyridine derivatives and medical composition thereof | YAMANOUCHI PHARMACUEITCAL CO L (JP) | 1997-08-06 | — | — | CN | disclosed |
| EP-0469547-B1 | 4-Amino-delta4,6-steroids and their use as 5alpha-reductase inhibitors | MERRELL PHARMA INC (US) | 1996-05-15 | — | — | EP | disclosed |
| US-5464833-A | Anticarcinogenic agents, antiretrovirus agents or autoimmune diseases | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0623598-A1 | APOPTOSIS REGULATOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
| CN-1091288-A | The oxytocin antagonist | OTSUKA PHARMA CO LTD (JP) | 1994-08-31 | — | — | CN | disclosed |
| US-5189032-A | Blocking the formation of dihydroxytestosterone from testosterone | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-02-23 | — | — | US | disclosed |
| US-5130424-A | Acne, skin disorders, scandular disorders | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-14 | — | — | US | disclosed |
| EP-0469547-A2 | 4-Amino-delta4,6-steroids and their use as 5alpha-reductase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1992-02-05 | — | — | EP | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | MAPT 4518/4885KMT2A 1134/4885MAPK1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.